Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Introduction. Antitumor necrosis factor‐alpha (TNF‐α) agents are widely used for treatment
of rheumatic and dermatological diseases. We conducted the systematic review and meta …

The emergence of tumor necrosis factor-α (TNF-α)-targeted therapies as a key therapeutic
option for patients with rheumatic, digestive, and dermatologic autoimmune diseases has …

An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Biologic therapies like adalimumab are the gold standard for psoriasis treatment with
efficacy and safety profiles allowing for long-term treatment. However, adalimumab cannot …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

Background No consensus exists regarding the optimal laboratory screening for hepatitis B
infection that should be performed before initiating therapy with tumor necrosis factor-alfa …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …